Merck to Present Long-Term Efficacy Data on GARDASIL9 and GARDASIL at EUROGIN 2026

Merck has announced plans to present new data on the long-term efficacy of its HPV vaccines, GARDASIL®9 and GARDASIL®, at the EUROGIN International Multidisciplinary HPV Congress in 2026. The findings will focus on the sustained effectiveness of these vaccines in preventing certain types of human papillomavirus (HPV)-related diseases over an extended period. The presentation aims to provide updated insights into the role of these vaccines in addressing HPV-related health concerns.

The EUROGIN Congress serves as a platform for experts to discuss advancements in HPV research, prevention, and treatment strategies. Merck’s presentation will include detailed analyses from ongoing studies that evaluate the durability of immune responses and protection offered by GARDASIL®9 and GARDASIL®. These vaccines are designed to protect against multiple strains of HPV, which can lead to cervical cancer and other related conditions. The company’s participation highlights its continued commitment to contributing data that informs global public health efforts surrounding HPV prevention.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: March 17, 2026

Author

GOAI